Alogliptin protects against cardiovascular disease by moderating micro-RNA for diabetic patients

Trial Profile

Alogliptin protects against cardiovascular disease by moderating micro-RNA for diabetic patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Alogliptin (Primary) ; Acarbose; Antihyperglycaemics; Voglibose
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 11 Jun 2013 Drug changed from Voglibose to Acarbose as in treatment arm as reported by University Hospital Medical Information Network - Japan.
    • 11 Jun 2013 Planned initiation date changed from 10 Jan 2013 to 20 Jun 2013 as reported by University Hospital Medical Information Network - Japan.
    • 23 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top